Ameer L. Elaimy

Ameer L. Elaimy

Auto-generated profile, based on publicly available information

Ameer L. Elaimy

Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
AEAmeer L. Elaimy
Ameer L. Elaimy
AMArthur M. Mercurio
Arthur M. Mercurio
Links from VEGF to YAP/TAZ signaling reveal ways to block angiogenesis and tumor cell plasticity.

1 May 2018 in Science Signaling
Verified
Journal Article
Open access
PDF file
AEAmeer L. Elaimy
Ameer L. Elaimy
SGSantosh Guru
Santosh Guru
CCCheng Chang
Cheng Chang
JOJianhong Ou
Jianhong Ou
JAJohn J. Amante
John J. Amante
AMArthur M. Mercurio
Arthur M. Mercurio
The growth factor VEGF induces a Rac1-TAZ–mediated positive feedback loop that sustains the proliferation of stem-like cells in breast cancer.

31 July 2019 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
AEAmeer L. Elaimy
Ameer L. Elaimy
MWMengdie Wang
Mengdie Wang
ASAnkur Sheel
Ankur Sheel
CBCaitlin W. Brown
Caitlin W. Brown
MWMelanie R. Walker
Melanie R. Walker
AMArthur M. Mercurio
Arthur M. Mercurio
The ability to monitor changes in the expression and localization of integrins is essential for understanding their contribution to development, tissue homeostasis and disease. Here, we pioneered the use of Crispr/Cas9 genome editing to tag an allele of the β4 subunit of the α6β4 integrin. A tdTomato tag was inserted with a linker at the C-terminus of integrin β4 in mouse mammary epithelial cells. Cells harboring this tagged allele were similar to wild-type cells with respect to integrin β4 surface expression, association with the α6 subunit, adhesion to laminin and consequent signaling. These integrin β4 reporter cells were transformed with YAP (also known as YAP1), which enabled us to obtain novel insight into integrin β4 dynamics in response to a migratory stimulus (scratch wound) by live-cell video microscopy. An increase in integrin β4 expression in cells proximal to the wound edge was evident, and a population of integrin β4-expressing cells that exhibited unusually rapid migration was identified. These findings could shed insight into integrin β4 dynamics during invasion and metastasis. Moreover, these integrin β4 reporter cells should facilitate studies on the contribution of this integrin to mammary gland biology and cancer. This article has an associated First Person interview with the first author of the paper.

18 August 2021
Verified
Book Chapter
Open access
PDF file
AEAmeer L. Elaimy
Ameer L. Elaimy
LDLinda Ding
Linda Ding
CBCarla Bradford
Carla Bradford
YGYansong Geng
Yansong Geng
HBHarry Bushe
Harry Bushe
KUKenneth Ulin
Kenneth Ulin
The use of proton therapy in oncology is not a new idea. The unique physical properties of protons and potential advantages in radiation therapy were initially recognized in the 1940s. Since the first patients were treated in the 1950s, technology and clinical applications have evolved as evidenced by the increasing number of proton therapy centers and patients being treated throughout the world. This chapter will review the history of proton therapy providing a detailed overview of the cyclotron and synchrotron techniques used and how they have advanced with time.

28 May 2021
Verified
Book Chapter
Open access
PDF file
TWTao Wang
Tao Wang
BLBrian Lewis
Brian Lewis
AEAmeer Elaimy
Ameer Elaimy
MRMarcus Ruscetti
Marcus Ruscetti
MSMitchell Sokoloff
Mitchell Sokoloff
TFThomas (TJ) FitzGerald
Thomas (TJ) FitzGerald
Adenocarcinoma of the prostate is a common malignancy affecting one in nine men, with six of every 10 cases identified in men older than 66 years, and more adversely affects African American males. It remains less common in men under the age of 40. The age adjusted incidence is increasing with the application of prostate specific antigen (PSA) as a biomarker. PSA helps identifying the disease at an early stage, which is treatable and curable with traditional therapies. However, a significant percentage of men present with high Gleason grade and advanced disease, with lower PSA, and younger age at presentation. These patients can have a compromised outcome. Once again, we are evaluating patients under the age of 50 with advanced disease due in part to inconsistent application of clinical screening. More effort is needed for high-risk patients to provide timely, meaningful intervention and effective therapy. In this chapter, we review the status of therapy for standard and high-risk patients, and strategies for translational science for patients at risk of compromised outcome and treatment failure.